Dawnrays has been listed on the Main Board of Hong Kong Stock Exchange Market.The Group is engaged in the development, manufacturing and the sale of cephalosporin antibiotics, and various system specific medicines (generic drugs). Dawnrays has boosted its production capacity of cephalosporin bulk medicine to 1000 tons/year, and it is expected to become one of the main producers in China market.
more >
Year of Establishment:
1995
Total Number of Staff:
more than 500
Main Competitive Advantages:
N;
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Annual Turnover(USD):
choose not to disclose
Main Sales Markets:
Central/South America,Western Europe,Eastern Europe,Asia
Advantage Description: